Delmitide

Drug Profile

Delmitide

Alternative Names: Allotrap 1258; Rationally Designed Peptide 58; RDP 1258; RDP 58

Latest Information Update: 20 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genzyme Corporation
  • Developer Synt:em
  • Class Anti-inflammatories; Peptides
  • Mechanism of Action Cytokine inhibitors; Immunosuppressants; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Crohn's disease; Ulcerative colitis
  • Discontinued Atopic dermatitis; Barrett's oesophagus; Chemotherapy-induced damage; Diarrhoea; Heart transplant rejection; HIV infections; Interstitial cystitis; Multiple sclerosis; Psoriasis; Pulmonary fibrosis; Respiratory tract disorders; Uveitis

Most Recent Events

  • 26 May 2010 No development reported - Phase-I for Crohn's disease in USA (PO)
  • 26 May 2010 No development reported - Phase-I for Ulcerative colitis in USA (PO)
  • 26 May 2010 No development reported - Phase-II for Crohn's disease in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top